Skip to content

Author

Silvio Danese

We have 5 of 63 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Systematic Review: Inclusion of Patients With Difficult‐to‐Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies

Criteria to define difficult‐to‐treat (DTT) inflammatory bowel disease (IBD) have recently been proposed, yet the inclusion and participation of patients with DTT‐IBD in randomized controlled trials (RCTs) are heterogeneous and poorly defined.

T. Parigi, V. Solitano, H. Mekonnen et al. · 0 citations
Review Oct 2026

EFFICACY AND SAFETY OF ADVANCED THERAPIES AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.

BACKGROUND & AIMS Advanced therapies (ATs) are central to the management of moderate-to-severe ulcerative colitis (UC). The expanding therapeutic landscape and limited head-to-head trials necessitate updated comparative effectiveness analyses. We performed a systematic review and network meta-analysis (NMA) to assess t...

Pablo A. Olivera, Juan S. Lasa, Siddharth Singh et al. · 0 citations
Review Open access Sep 2026

Advanced Therapies for the Management of Immune Checkpoint Inhibitor-Induced Colitis

Simple Summary Immune checkpoint inhibitors help the body’s immune system attack tumors and have greatly improved survival for many cancer patients. However, by boosting the immune system, these drugs can also cause it to attack healthy tissue, and inflammation of the bowel is one of the most common and serious side ef...

C. S. Matichecchia, F. Fanizzi, A. Zilli et al. · 0 citations
Open access Sep 2026

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Upadacitinib was effective and well-tolerated in AT-experienced Crohn's disease, including patients with active EIMs, with induction benefit maintained through 6 months without novel safety signals.

B. Barberio, F. D'Amico, L. Laterza et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.